Report Detail

Pharma & Healthcare Global Friedreich Ataxia Drug Market Insights, Forecast to 2025

  • RnM3059624
  • |
  • 05 March, 2019
  • |
  • Global
  • |
  • 128 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

The global Friedreich Ataxia Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Friedreich Ataxia Drug market based on company, product type, end user and key regions.

This report studies the global market size of Friedreich Ataxia Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Friedreich Ataxia Drug in these regions.
This research report categorizes the global Friedreich Ataxia Drug market by top players/brands, region, type and end user. This report also studies the global Friedreich Ataxia Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Adverum Biotechnologies Inc
BioMarin Pharmaceutical Inc.
Biovista Inc.
Cardero Therapeutics Inc
Catabasis Pharmaceuticals, Inc.
Forward Pharma A/S
Ixchel Pharma LLC
Pfizer Inc
ProQR Therapeutics NV
RaNA Therapeutics Inc
Reata Pharmaceuticals Inc
Retrotope Inc
Shire Plc
STATegics Inc
Voyager Therapeutics Inc

Market size by Product
ADVM-063
AGIL-FA
BHV-4157
BVA-202
Others
Market size by End User
Clinic
Hospital
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Friedreich Ataxia Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Friedreich Ataxia Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Friedreich Ataxia Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Friedreich Ataxia Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Friedreich Ataxia Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Friedreich Ataxia Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


Table of Contents

    1 Study Coverage

    • 1.1 Friedreich Ataxia Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Friedreich Ataxia Drug Market Size Growth Rate by Product
      • 1.4.2 ADVM-063
      • 1.4.3 AGIL-FA
      • 1.4.4 BHV-4157
      • 1.4.5 BVA-202
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Friedreich Ataxia Drug Market Size Growth Rate by End User
      • 1.5.2 Clinic
      • 1.5.3 Hospital
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Friedreich Ataxia Drug Market Size
      • 2.1.1 Global Friedreich Ataxia Drug Revenue 2014-2025
      • 2.1.2 Global Friedreich Ataxia Drug Sales 2014-2025
    • 2.2 Friedreich Ataxia Drug Growth Rate by Regions
      • 2.2.1 Global Friedreich Ataxia Drug Sales by Regions
      • 2.2.2 Global Friedreich Ataxia Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Friedreich Ataxia Drug Sales by Manufacturers
      • 3.1.1 Friedreich Ataxia Drug Sales by Manufacturers
      • 3.1.2 Friedreich Ataxia Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Friedreich Ataxia Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Friedreich Ataxia Drug Revenue by Manufacturers
      • 3.2.1 Friedreich Ataxia Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Friedreich Ataxia Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Friedreich Ataxia Drug Price by Manufacturers
    • 3.4 Friedreich Ataxia Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Friedreich Ataxia Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Friedreich Ataxia Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Friedreich Ataxia Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Friedreich Ataxia Drug Sales by Product
    • 4.2 Global Friedreich Ataxia Drug Revenue by Product
    • 4.3 Friedreich Ataxia Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Friedreich Ataxia Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Friedreich Ataxia Drug by Countries
      • 6.1.1 North America Friedreich Ataxia Drug Sales by Countries
      • 6.1.2 North America Friedreich Ataxia Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Friedreich Ataxia Drug by Product
    • 6.3 North America Friedreich Ataxia Drug by End User

    7 Europe

    • 7.1 Europe Friedreich Ataxia Drug by Countries
      • 7.1.1 Europe Friedreich Ataxia Drug Sales by Countries
      • 7.1.2 Europe Friedreich Ataxia Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Friedreich Ataxia Drug by Product
    • 7.3 Europe Friedreich Ataxia Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Friedreich Ataxia Drug by Countries
      • 8.1.1 Asia Pacific Friedreich Ataxia Drug Sales by Countries
      • 8.1.2 Asia Pacific Friedreich Ataxia Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Friedreich Ataxia Drug by Product
    • 8.3 Asia Pacific Friedreich Ataxia Drug by End User

    9 Central & South America

    • 9.1 Central & South America Friedreich Ataxia Drug by Countries
      • 9.1.1 Central & South America Friedreich Ataxia Drug Sales by Countries
      • 9.1.2 Central & South America Friedreich Ataxia Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Friedreich Ataxia Drug by Product
    • 9.3 Central & South America Friedreich Ataxia Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Friedreich Ataxia Drug by Countries
      • 10.1.1 Middle East and Africa Friedreich Ataxia Drug Sales by Countries
      • 10.1.2 Middle East and Africa Friedreich Ataxia Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Friedreich Ataxia Drug by Product
    • 10.3 Middle East and Africa Friedreich Ataxia Drug by End User

    11 Company Profiles

    • 11.1 Adverum Biotechnologies Inc
      • 11.1.1 Adverum Biotechnologies Inc Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Adverum Biotechnologies Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Adverum Biotechnologies Inc Friedreich Ataxia Drug Products Offered
      • 11.1.5 Adverum Biotechnologies Inc Recent Development
    • 11.2 BioMarin Pharmaceutical Inc.
      • 11.2.1 BioMarin Pharmaceutical Inc. Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Products Offered
      • 11.2.5 BioMarin Pharmaceutical Inc. Recent Development
    • 11.3 Biovista Inc.
      • 11.3.1 Biovista Inc. Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Biovista Inc. Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Biovista Inc. Friedreich Ataxia Drug Products Offered
      • 11.3.5 Biovista Inc. Recent Development
    • 11.4 Cardero Therapeutics Inc
      • 11.4.1 Cardero Therapeutics Inc Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Cardero Therapeutics Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Cardero Therapeutics Inc Friedreich Ataxia Drug Products Offered
      • 11.4.5 Cardero Therapeutics Inc Recent Development
    • 11.5 Catabasis Pharmaceuticals, Inc.
      • 11.5.1 Catabasis Pharmaceuticals, Inc. Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Products Offered
      • 11.5.5 Catabasis Pharmaceuticals, Inc. Recent Development
    • 11.6 Forward Pharma A/S
      • 11.6.1 Forward Pharma A/S Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Forward Pharma A/S Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Forward Pharma A/S Friedreich Ataxia Drug Products Offered
      • 11.6.5 Forward Pharma A/S Recent Development
    • 11.7 Ixchel Pharma LLC
      • 11.7.1 Ixchel Pharma LLC Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Ixchel Pharma LLC Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Ixchel Pharma LLC Friedreich Ataxia Drug Products Offered
      • 11.7.5 Ixchel Pharma LLC Recent Development
    • 11.8 Pfizer Inc
      • 11.8.1 Pfizer Inc Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Pfizer Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Pfizer Inc Friedreich Ataxia Drug Products Offered
      • 11.8.5 Pfizer Inc Recent Development
    • 11.9 ProQR Therapeutics NV
      • 11.9.1 ProQR Therapeutics NV Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 ProQR Therapeutics NV Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 ProQR Therapeutics NV Friedreich Ataxia Drug Products Offered
      • 11.9.5 ProQR Therapeutics NV Recent Development
    • 11.10 RaNA Therapeutics Inc
      • 11.10.1 RaNA Therapeutics Inc Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 RaNA Therapeutics Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 RaNA Therapeutics Inc Friedreich Ataxia Drug Products Offered
      • 11.10.5 RaNA Therapeutics Inc Recent Development
    • 11.11 Reata Pharmaceuticals Inc
    • 11.12 Retrotope Inc
    • 11.13 Shire Plc
    • 11.14 STATegics Inc
    • 11.15 Voyager Therapeutics Inc

    12 Future Forecast

    • 12.1 Friedreich Ataxia Drug Market Forecast by Regions
      • 12.1.1 Global Friedreich Ataxia Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Friedreich Ataxia Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Friedreich Ataxia Drug Market Forecast by Product
      • 12.2.1 Global Friedreich Ataxia Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Friedreich Ataxia Drug Revenue Forecast by Product 2019-2025
    • 12.3 Friedreich Ataxia Drug Market Forecast by End User
    • 12.4 North America Friedreich Ataxia Drug Forecast
    • 12.5 Europe Friedreich Ataxia Drug Forecast
    • 12.6 Asia Pacific Friedreich Ataxia Drug Forecast
    • 12.7 Central & South America Friedreich Ataxia Drug Forecast
    • 12.8 Middle East and Africa Friedreich Ataxia Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Friedreich Ataxia Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Summary:
      Get latest Market Research Reports on Friedreich Ataxia Drug . Industry analysis & Market Report on Friedreich Ataxia Drug is a syndicated market report, published as Global Friedreich Ataxia Drug Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Friedreich Ataxia Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,084.90
      4,627.35
      6,169.80
      3,595.80
      5,393.70
      7,191.60
      605,670.00
      908,505.00
      1,211,340.00
      325,650.00
      488,475.00
      651,300.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report